Literature DB >> 33318014

Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

Ahizechukwu C Eke1,2, Kensuke Shoji3, Brookie M Best4,5, Jeremiah D Momper4, Alice M Stek6, Tim R Cressey7,8, Mark Mirochnick9, Edmund V Capparelli4,5.   

Abstract

Pharmacokinetics of drugs can be affected by physiologic changes during pregnancy. Our aim was to assess the influence of covariates on tenofovir (TFV) pharmacokinetics in pregnant and postpartum women receiving tenofovir disoproxil fumarate (TDF). Population pharmacokinetic parameter estimates and the influence of covariates were assessed using nonlinear mixed-effects modeling (NONMEM 7.4). Forty-six women had intensive pharmacokinetic evaluations during the second and third trimesters of pregnancy, with another evaluation postpartum. A two-compartment pharmacokinetic model with allometric scaling for body weight and first-order absorption best described the tenofovir plasma concentration data. Apparent oral clearance (CL/F) and volume of distribution at steady state (Vss/F) were increased during pregnancy. Weight, serum creatinine (SCr), pregnancy, albumin, and age were associated with TFV CL/F during univariate assessment, but in the multivariate analysis, changes in CL/F and Vss/F were only associated with increased body weight and enhanced renal function. Due to greater weight and lower SCr during pregnancy, CL/F was 28% higher during pregnancy than postpartum. In the final model, CL/F (liters per hour) was described as 2.07 × (SCr/0.6)0.65 × weight0.75, with a low between-subject variability (BSV) of 24%. The probability of target attainment (proportion exceeding area under the concentration-time curve of >1.99 μg·h/ml, the 10th percentile of average TFV exposure for nonpregnant historical controls) was 68%, 80%, 87%, and 93% above the target with 300 mg, 350 mg, 400 mg, and 450 mg of TDF, respectively, during pregnancy and 88%, 92%, 96%, and 98% above the target with same doses in postpartum women. Dose adjustment of TDF during pregnancy is not generally warranted, but any modification should be based on weight and renal function. (This study has been registered at ClinicalTrials.gov under identifier NCT00042289.).
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  AIDS; HIV; TDF; population pharmacokinetics; postpartum; pregnancy; tenofovir; tenofovir disoproxil fumarate

Mesh:

Substances:

Year:  2021        PMID: 33318014      PMCID: PMC8092509          DOI: 10.1128/AAC.02168-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  31 in total

1.  Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.

Authors:  Edmund S Ho; Deborah C Lin; Dirk B Mendel; Tomas Cihlar
Journal:  J Am Soc Nephrol       Date:  2000-03       Impact factor: 10.121

2.  Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.

Authors:  Marta Boffito; Anton Pozniak; Brian P Kearney; Christopher Higgs; Anita Mathias; Lijie Zhong; Jaymin Shah
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

Authors:  Sihem Benaboud; Déborah Hirt; Odile Launay; Emmanuelle Pannier; Ghislaine Firtion; Elisabeth Rey; Naïm Bouazza; Frantz Foissac; Hélène Chappuy; Saik Urien; Jean Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

4.  Mechanism of active renal tubular efflux of tenofovir.

Authors:  Adrian S Ray; Tomas Cihlar; Kelly L Robinson; Leah Tong; Jennifer E Vela; Michael D Fuller; Lani M Wieman; Eugene J Eisenberg; Gerry R Rhodes
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.

Authors:  Rémon A M H van Aubel; Pascal H E Smeets; Janny G P Peters; René J M Bindels; Frans G M Russel
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

6.  Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Authors:  Stephen A Greene; Jingxian Chen; Heather M A Prince; Craig Sykes; Amanda P Schauer; Kimberly Blake; Julie A E Nelson; Cynthia L Gay; Myron S Cohen; Julie B Dumond
Journal:  Clin Pharmacol Ther       Date:  2019-05-31       Impact factor: 6.875

Review 7.  Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Authors:  Adrian S Ray; Marshall W Fordyce; Michael J M Hitchcock
Journal:  Antiviral Res       Date:  2015-11-27       Impact factor: 5.970

8.  Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.

Authors:  M Robert Blum; Gregory E Chittick; John A Begley; Jian Zong
Journal:  J Clin Pharmacol       Date:  2007-06       Impact factor: 3.126

9.  Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.

Authors:  Lucie Durand-Gasselin; Koen K A Van Rompay; Jennifer E Vela; Ilana N Henne; William A Lee; Gerry R Rhodes; Adrian S Ray
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

Review 10.  Physiologic and pharmacokinetic changes in pregnancy.

Authors:  Maged M Costantine
Journal:  Front Pharmacol       Date:  2014-04-03       Impact factor: 5.810

View more
  4 in total

1.  Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.

Authors:  Regis Kreitchmann; Alice Stek; Brookie M Best; Edmund Capparelli; JiaJia Wang; David Shapiro; Nahida Chakhtoura; Mark Mirochnick; Ahizechukwu C Eke
Journal:  Contraception       Date:  2021-08-15       Impact factor: 3.375

Review 2.  Prediction and prevention of preterm birth in pregnant women living with HIV on antiretroviral therapy.

Authors:  Amanda J Jones; Uzoamaka A Eke; Ahizechukwu C Eke
Journal:  Expert Rev Anti Infect Ther       Date:  2022-03-01       Impact factor: 5.854

3.  Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF).

Authors:  Matthew A Thimm; Alison Livingston; Rosemary Ramroop; Ahizechukwu C Eke
Journal:  J AIDS HIV Treat       Date:  2022

4.  Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.

Authors:  Ahizechukwu C Eke
Journal:  J Pharm Drug Res       Date:  2022-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.